Release of Active TGF-β1 from the Latent TGF-β1/GARP Complex on T Regulatory Cells Is Mediated by Integrin β8

Justin P. Edwards, Angela M. Thornton and Ethan M. Shevach

*J Immunol* 2014; 193:2843-2849; Prepublished online 15 August 2014;
doi: 10.4049/jimmunol.1401102
http://www.jimmunol.org/content/193/6/2843

Supplementary Material
http://www.jimmunol.org/content/suppl/2014/08/15/jimmunol.1401102.DCSupplemental

References
This article cites 22 articles, 15 of which you can access for free at:
http://www.jimmunol.org/content/193/6/2843.full#ref-list-1

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Release of Active TGF-β1 from the Latent TGF-β1/GARP Complex on T Regulatory Cells Is Mediated by Integrin β8

Justin P. Edwards, Angela M. Thornton, and Ethan M. Shevach

Activated T regulatory cells (Tregs) express latent TGF-β1 on their cell surface bound to GARP. Although integrins have been implicated in mediating the release of active TGF-β1 from the complex of latent TGF-β1 and latent TGF-β1 binding protein, their role in processing latent TGF-β1 from the latent TGF-β1/GARP complex is unclear. Mouse CD4+Foxp3+ Treg, but not CD4+ Foxp3- T cells, expressed integrin β8 (Itgb8) as detected by quantitative RT-PCR. Itgb8 expression was a marker of thymically derived (t)Tregs and functions in a cell intrinsic manner in mediating the processing of latent TGF-β1 from the latent TGF-β1/GARP complex on the surface of tTregs. The Journal of Immunology, 2014, 193: 2843–2849.

Activated Foxp3+ T regulatory cells (Tregs) express the latent TGF-β1 binding protein GARP/LRRC32 that is required for expression of latent TGF-β1 on the surface of human and mouse Tregs. In an in vitro culture system in which activated Tregs are used as source of TGF-β1 to drive induced Treg (iTreg) or Th17 differentiation, GARP is required for efficient production of biologically active TGF-β1 (1). Previous studies have indicated, among other mechanisms, that the αv integrins, αvβ6 and αvβ8, bind the arginine-glycine-aspartic acid (RGD) site in latent TGF-β1 and facilitate the release of biologically active TGF-β1 from the complex of latent TGF-β1 and latent TGF-β1 binding protein (LTBP, the large latent complex). Activation mediated by αvβ6 requires the interaction of its cytoplasmic domain with the actin cytoskeleton, which appears to drive the shear forces needed to activate TGF-β1 from large latent complex (2). In contrast, αvβ8 has a short cytoplasmic tail that does not interact with the actin cytoskeleton. Some studies have demonstrated αvβ8-dependent processing of latent TGF-β1 from the large latent complex requires the coexpression of matrix metalloproteases (MMPs), specifically MMP-14 (or MT1-MMP) (3). It is unknown, however, if this is the only MMP that can function in αvβ8-mediated activation of TGF-β1.

Previous studies have focused on processing of latent TGF-β1 from the large latent complex by integrin αvβ8 on dendritic cells (DCs). Conditional deletion of Itgb8 from leukocytes or only from DCs resulted in severe inflammatory bowel disease and age-related autoimmunity (4). Deletion of Itgb8 on DCs also resulted in an inability to drive endogenous Th17 differentiation in the gut and in a failure to generate highly pathogenic Th17 cells during experimental autoimmune encephalomyelitis resulting in markedly milder symptoms (5). The role of integrins in processing latent TGF-β1 from the latent TGF-β1/GARP complex is less clear. αvβ6, and to a lesser extent αvβ8, were shown to activate latent TGF-β1 from 293 cells transfected with αv integrins, pro-TGF-β1, and GARP (6). However, interpretation of these studies was complicated by the fact that TGF-β1 was equally activated in the absence of GARP, probably because of the presence of endogenous LTBP. Nevertheless, it appeared that the ability of αvβ8 to activate TGF-β1 from the latent TGF-β1/GARP complex was real because it was preserved in the presence of the ECR3E fragment of LTBP, which inhibits endogenous LTBP, but not GARP. It remains unclear whether similar mechanisms are present in Tregs or platelets that physiologically express GARP.

The purpose of the current study was to examine how biologically active TGF-β1 is released from the GARP/laten TGF-β1 complex by mouse Tregs. In this study, we demonstrate that integrin αvβ8 is a marker of mouse thymically derived (t)Tregs and functions in a cell-intrinsic manner to release active TGF-β1.

Materials and Methods

Mice

C57BL/6 were obtained from the National Center Institute Mouse Repository (Frederick, MD), Foxp3-GFP, C57BL/6-Rag1-/-, and OVA-specific TCR-transgenic OT-II (CD45.1, Rag1-/-) mice were obtained by the National Institute of Allergy and Infectious Diseases (NIAID) and were maintained by Taconic Farms (Germantown, NY) under contract by NIAID. Itgb8<sup>loxP/loxP</sup> mice, which have been previously described (7), were obtained from the Mutant Mouse Regional Resource Center (MMRRC stock number 014108-UCD). These mice contain loxP sites within 3' and 5' introns of exon 4 of the Itgb8 gene. Lrrc32<sup>+/LOX</sup> (GARP) and Tgfb1<sup>+/LOX</sup>, Rck2<sup>+/Helios</sup> (Helios) mice have been described previously (1, 8, 9). Floxed mice were crossed to CD4-CRE mice (Taconic). Helios-GFP reporter mice were developed by Taconic Artemis and will be described in detail at a later date. Helios-GFP reporter mice were crossed to Foxp3-mRFP mice obtained from The Jackson Laboratory (Bar Harbor, ME). OVA-specific TCR-transgenic OT-II mice were obtained from Taconic Farms and bred to

Cellular Immunology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

Received for publication April 30, 2014. Accepted for publication July 16, 2014.

This work was supported by funds from the Intramural Program of the National Institute of Allergy and Infectious Diseases.

Address correspondence and reprint requests to Dr. Ethan M. Shevach, Cellular Immunology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N315, 10 Center Drive, MSC 1892, Bethesda, MD 20892. E-mail address: ESHEVACH@niaid.nih.gov

The online version of this article contains supplemental material.

Abbreviations used in this article include: eκO, conditional knock-out; DC, dendritic cell; Itgb8, integrin β8; iTreg, induced Treg; KO, knockout; LAP, latency-associated peptide; LTBP, latent TGF-β binding protein; MMP, matrix metalloprotease; NIAID, National Institute of Allergy and Infectious Diseases; qRT-PCR, quantitative real-time PCR; RGD, arginine-glycine-aspartic acid; Tconv, conventional T cell; Treg, T regulatory cell; tTreg, thymically derived Treg; WT, wild-type.
Foxp3-GFP mice to generate OT-II Foxp3-GFP mice, as described previously (10). All animal protocols used in this study were approved by the NIAID Animal Care and Use Committee.

**Inflammatory bowel disease experiments**

Inflammatory bowel disease experiments were performed similarly to those described previously (11). Briefly, 4 × 10⁷ naive wild-type (WT) CD4⁺ T-cells (CD4⁺CD25⁻CD45RB⁺) were transferred into Rag1⁻⁄⁻ mice in the presence or absence of 2 × 10⁴ CD4⁺CD25⁺CD45RB⁻ Tregs from WT or Itgb8 conditional knockout (cKO) mice. Weights were monitored two weeks weekly for up to 11 wk.

**Cell isolation and flow cytometry**

For purification of DCs, mouse spleens were fragmented and digested for 30 min at 37°C in the presence of liberase blendzyme II (Roche) and DNase (2 μg/ml) (Roche) in complete medium (modified RPMI 1640 medium supplemented with 10% FBS HyClone, 50 μM 2-ME (Sigma-Aldrich), 1% sodium pyruvate, 1% nonessential amino acids, 1% HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM l-glutamine. They were labeled with anti-CD11c beads and purified on the AutoMACS Cell Separator (Miltenyi Biotec). T cells from pooled lymph nodes and/or spleens were isolated using CD4 beads.

CD4⁺Foxp3⁺ Tregs and Foxp3⁻ conventional T cells (Tconv) were sorted from the pooled lymph node and/or Foxp3-GFP mice. CD4⁺CD25⁺ Treg and CD4⁺CD25⁻ Tconv also were sorted. All cell sorting was performed on FACSaria flow cytometers (BD Biosciences). Single-cell suspensions were stained using the following Abs according to the manufacturer’s protocol: anti-mouse CD45.1 (A20), CD45.2 (104), CD4 (RM4-5), Foxp3 (FLK-16s), GARP (YGIC86), and IL-17A (eBio17B7). Purified mouse anti-mouse LAP clone 7T7-16B4 was provided by H. Weiner (Harvard Medical School, Boston, MA). The LAP Ab was labeled with SureLight-APC at Columbia Biosciences (Columbia, MD). For staining of Foxp3, cells were fixed and permeabilized using the Bio-Permeabilization Permeabilization Kit (eBioscience). For staining of cytokines, cells were fixed and permeabilized using the Cytofix/Cytoperm Kit from BD Biosciences.

**Cytokines and other reagents**

Recombinant mouse IL-6 was purchased from BioLegend (San Diego, CA). The MMP inhibitor GM6001 and the GM6001 control were both purchased from Santa Cruz Biotechnology (Dallas, TX).

**In vitro suppression assay**

In vitro suppression assays were performed as described previously (12).

**In vitro T cell differentiation**

To induce Th17 or iTreg differentiation using activated Tregs as a source of bioactive TGF-beta1 as previously described (1), sorted Tregs were activated and expanded using plate-bound anti-CD3 (1 μg/well, 24-well plate) with IL-2 (10 U/ml) for 2–3 d, followed by overnight culture with IL-2 alone. Cells were generally >90–95% Foxp3⁺ after expansion. Tregs were washed and mixed 1:1 with naive CD45.1 OT-II cells (RAG1⁻⁻/⁻) in the presence of recombinant mouse IL-6 (10 ng/ml) and stimulated with splenic DCs and soluble anti-CD3 for 4 d. Similar experiments were performed using exogenous IL-2 (100 U/ml) and activated Tregs to drive iTreg differentiation. Th17-differentiated T cells were stimulated with the Cell Stimulation Cocktail and Protein Transport Inhibitors (eBioscience).

In other experiments, iTregs were differentiated to analyze the expression of Itgb8. Naive CD4⁺ T cells (CD44⁻CD62L⁺) from Foxp3-GFP mice were cultured with plate-bound anti-CD3 or DCs and soluble anti-CD3. Naive CD4⁺ T cells were also sorted from OT-II Foxp3-GFP mice and cultured with splenic DCs and cognate peptide. In all conditions, cells were cultured in the presence of recombinant TGF-beta1 and IL-2. After 4 d of culture, CD4⁺GFP (Foxp3⁺) cells were sorted and immediately subjected to RNA isolation.

**mRNA isolation, cDNA production, and real-time PCR**

Tregs and conventional CD4⁺ T cells were sorted and immediately subjected to RNA extraction or stimulated overnight with IL-2 and plate-bound anti-CD3 then subjected to RNA extraction using TRIzol reagent. The contaminating DNA was then removed by DNase I treatment. The SuperScript II First-Strand Synthesis Supermix for quantitative real-time PCR (qRT-PCR; Invitrogen Life Technologies) was used to generate cDNA. Real-time PCR was performed with the ABI Prism7900HT, using the Kapa Probe Fast Universal qPCR Kit and TaqMan Probes for GAPDH, ITGB8, and Foxp3.

**Results**

Integrin α₇β₈ is a marker of Foxp3⁺ Tregs

Previous studies from our group and others have demonstrated that activated Foxp3⁺ Tregs express latent TGF-beta1 on their cell surface bound to the tethering molecule, GARP (1, 13, 14). Although α₇β₈ on DCs has been shown to mediate the release of active TGF-beta1 from the large latent complex, we have previously shown that even in the absence of DCs, Tregs are able to release active TGF-beta1, primarily from the latent TGF-beta1/GARP complex (1). We therefore decided to examine the potential expression and function of α₇β₈ and β₇α₈ by Tregs. Sorted CD4⁺Foxp3⁺ expressed substantially higher levels of Itgb8 than CD4⁺Foxp3⁻ Tconvs by qRT-PCR (Fig. 1A). Neither cell type expressed Itgb6 (data not shown). Unfortunately, we could not determine the expression of β₈ on a single-cell basis, because no Ab is currently available for staining and FACs analysis. The expression of Itgb8 was not dependent on the expression of TGF-beta1 or GARP (Fig. 1B, 1C). However, both cell populations expressed integrin α₅ (CD51) either freshly isolated or after activation with anti-CD3 and IL-2 (Supplemental Fig. 1). CD51, however, is well known to be able to pair with multiple integrin β-chains in addition to β₈ including β₁, β₃, β₅, and β₆ (15).

Itgb8 expression on Tregs was not dependent on the lymphoid tissue from which the Tregs were isolated (Fig. 1D) and was only modestly increased upon activation (Fig. 1E). Itgb8 has been shown to be expressed in CD103⁺ DCs in the mesenteric lymph nodes or gut-associated lymphoid tissues (16, 17). We found that the level of expression of Itgb8 was higher in Tregs than in CD103⁺ DCs (relative to GAPDH). As previously described (17), the level of Itgb8 was substantially higher in CD103⁺ DCs from

![FIGURE 1. Integrin α₇β₈ is a marker of Foxp3⁺ Tregs. (A) Sorted CD4⁺Foxp3⁺ (GFP⁻) and CD4⁺Foxp3⁻ (GFP⁺) were measured for Itgb8 and Foxp3 message as measured by qRT-PCR. Data are expressed relative to CD4⁺Foxp3⁺ cells. (B) and (C) Sorted CD4⁺CD25⁻ and CD4⁺CD25⁺ from CD4 cKOs of Tgb8 and Lvn32 and their CRE⁻⁻/⁻ littermate controls were measured for Itgb8 message. Data are expressed relative to WT CD4⁺CD25⁻ cells. (D) Sorted CD4⁺Foxp3⁺ (GFP⁻) and CD4⁺Foxp3⁻ (GFP⁺) from spleen, peripheral lymph nodes, or mesenteric lymph nodes were measured for Itgb8 message as measured by qRT-PCR. (E) Sorted CD4⁺ Foxp3⁺ (GFP⁻) and CD4⁺Foxp3 (GFP⁺) from spleen, peripheral lymph nodes, or mesenteric lymph nodes were measured for Itgb8 message. DCs were first gated on Thy1.2 CD19⁻ CD11c⁻/⁻ cells.](http://www.jimmunol.org/DownloadedFrom)
the mesenteric lymph nodes than in CD103− DCs or DC populations from the spleen (Fig. 1E).

Integrin β8 is expressed primarily by Helios+Foxp3+ Tregs

Because we have previously shown that iTregs express the latent TGF-β1/GARP complex, it was of interest to determine whether iTreg also express Itgb8 (1). iTregs were generated from naive CD4+Foxp3+ T cells from Foxp3-GFP or OT-II Foxp3-GFP mice. iTregs were generated using plate-bound anti-CD3, splenic DCs with soluble anti-CD3, or splenic DCs with OVA peptide (OT-II cells) cultured for 4 d with IL-2 and TGF-β1 and then sorted for Foxp3+ (GFP+) cells. Tregs and Foxp3+ cells stimulated with plate-bound anti-CD3+IL-2 were cultured in parallel and sorted for GFP+ or GFP− cells, respectively. iTregs generated with plate-bound anti-CD3 did not express substantial levels of Itgb8 nor did those generated using DCs with peptide. Tregs cultured in parallel maintained their expression, whereas cultured Foxp3+ cells did not show substantial expression. Interestingly, iTregs generated using splenic DCs and soluble anti-CD3 did show some expression of Itgb8, whereas those generated using more physiologically relevant conditions with peptide did not. The level of expression by iTregs generated using splenic DCs and soluble anti-CD3 was still lower than cultured Tregs (Fig. 2A). As we have previously proposed (9) that Foxp3+Helios+ and Foxp3+Helios− Tregs may represent iTreg and peripherally derived Tregs, respectively, the relative expression of Itgb8 was determined for each of these populations. CD4+Foxp3+Helios+, CD4+Foxp3+Helios−, and CD4+ Foxp3+Helios− cells were isolated from a Helios(GFP)/Foxp3(RFP) double-reporter mouse. Only the CD4+Foxp3+Helios+ cells expressed substantial levels of Itgb8 (Fig. 2B). Furthermore, this difference in expression was maintained even after activation and expansion for 4 d in culture (Fig. 2C). Helios did not control the expression of Itgb8, because Tregs sorted from IκB2(Helios)Ikzf2(CRE)1 CD4-CRE cKO mice maintained their expression of Itgb8 (Fig. 2D).

Itgb8 is required for clearance of TGF-β1 from the GARP/latent-TGF-β1 complex

To investigate the function of Itgb8 on Tregs, we bred CD4-cKOs of Itgb8, using the previously described Itgb8Fopf1 mice (7). When bred with the CD4-CRE, the percentages of thymocyte subpopulations (Supplemental Fig. 2, upper panels), including the percentages of Foxp3+ cells within the CD4 single-positive population (Supplemental Fig. 2, lower panels), were identical in CRE+ and CRE− littermates. The percentages of CD4+Foxp3− and CD4+Foxp3+ T cells in the periphery were also identical in CRE+ and CRE− littermates (Supplemental Fig. 2, right panels).

We hypothesized that if αvβ8 is involved in activation of TGF-β1 from the GARP/latent-TGF-β1 complex, that in the absence of Itgb8, latent-TGF-β1 would accumulate on the surface of Tregs. Freshly isolated Tregs from WT and Itgb8 cKO mice displayed similar low levels of cell surface-latent-TGF-β1, whereas after activation, cKO Tregs displayed significantly higher levels of latent-TGF-β1 than activated WT Tregs (Fig. 3A, 3B). Because resting Tregs express higher level of GARP than latent TGF-β1, it is likely that the levels of latent TGF-β1 are probably limiting in forming the expression of the GARP/latent-TGF-β1 complex on the cell surface. Itgb8 cKO mice also expressed higher levels of GARP and GARP/LAP double-positive cells (Fig. 3B).

Itgb8 is not required for Treg-mediated suppression in vitro or in vivo in a transfer model of colitis

We next determined whether Treg expression of Itgb8 is required for suppression of T effector cell proliferation in vitro. Using the traditional T cell suppression assay, Tregs from both Itgb8 cKO and WT floxed littermates equally suppressed proliferation with increasing ratios of Treg to effector T cells (Fig. 4A). This was not unexpected, however, because it has previously been shown by our group and others that neither TGF-β1 nor GARP expression is required for in vitro suppression (1, 8). Next, we determined whether Itgb8 plays a role in Treg-mediated suppression in the transfer model of colitis. Transfer of WT CD4+CD25+CD45RBhi T cells resulted in significant weight loss in the recipients; both WT and cKO Tregs were equally capable of protecting from disease (Fig. 4B). Importantly, 75 d posttransfer, both WT and cKO Tregs equally maintained Foxp3+ cells in the mesenteric lymph nodes (Fig. 4C, 4D). This result is consistent with a previous report (18), which demonstrated that TGF-β1 was required for suppression of inflammatory bowel disease in this model but that the source of the TGF-β1 was not the Treg.

ITGB8 expression by Tregs is required for the bioavailability of active TGF-β1 from Tregs

To evaluate the availability of biologically active TGF-β1 released from WT and Itgb8 cKO Tregs, we used an in vitro culture system in which activated Tregs are cultured with naive T cells under activating conditions (splenic DCs with soluble anti-CD3) in the
presence of IL-6 or IL-2 to drive Th17 or iTreg differentiation, respectively. We have previously shown that TGF-β1 derived from the TGF-β1/GARP complex plays a major role as the source of TGF-β1 required for differentiation of Th17 cells or iTreg (1). WT, but not Itgb8 cKO, Tregs, promoted the differentiation of Th17 or iTreg as measured by IL-17A and Foxp3 expression, respectively (Fig. 5A, 5B). The same result was observed when the Tregs were only activated overnight prior to being cultured with naive cells (data not shown). To determine whether the GARP/latent-TGF-β1 complex and αvβ8 needed to be expressed on the same cells or whether αvβ8 expressed on one cell could result in the activation of TGF-β1 from the GARP/latent-TGF-β1 complex on a different cell, we cultured Tregs from GARP (Lrrc32) cKO or Itgb8 cKO mice separately or together with naive T cells in the Th17 differentiation assay. Neither GARP nor Itgb8 cKO cells alone could efficiently drive Th17 differentiation, however when mixed they were able to substantially restore Th17 differentiation, indicating that integrin αvβ8 expressed by human epithelial cell lines required the coexpression of an MMP, in particular MMP-14 (3), to activate latent TGF-β1 from the large latent complex. The contribution of MMP-14 was demonstrated by the use of the MMP inhibitor

FIGURE 3. Activated Itgb8-deficient Tregs accumulate latent TGF-β1 on their surface. (A and B) Freshly isolated cells from pooled lymph nodes and enriched CD4+ cells from Itgb8 cKO mice (CD4-CRE) or CRE+ littersmates were stimulated for 48 h with plate-bound anti-CD3 and IL-2 and then stained for CD4, Foxp3, LAP (or IC), and GARP (or IC). (A) Representative histograms for LAP (latent TGF-β1) from CD4+Foxp3+ cells. (B) Graphic representations indicating LAP and GARP mean fluorescence intensity on CD4+Foxp3+ cells as well as percentage of LAP and GARP double-positive cells.

FIGURE 4. Tregs from Itgb8 cKO mice suppress normally in vitro and in vivo. (A) T cell suppression assays using sorted CD4+CD25+ cells from WT mice in the presence or absence of increasing ratios of Itgb8 WT and KO CD4+CD25+ cells, as described previously (12). (B) WT CD4+CD25−CD45RBlo T cells were transferred into Rag1−/− mice in the presence or absence of CD4+CD25hiCD45RBhi Tregs from WT or Itgb8 cKO mice and monitored for weight loss for up to 11 wk. Indicated are the average weight changes from five mice in each group. (C and D) At the end of the experiment, mesenteric lymph nodes were stained for CD4 and Foxp3. (C) Representative lymph node samples. (D) The percentage of CD4+ cells that were Foxp3+ in individual mice.
GM6001. Thus far, we have not observed any effect of this inhibitor over a wide dose range on Treg-mediated Th17 induction up to 20 μM, as compared with the vehicle control or GM6001-control (Fig. 5E). It is important to note, however, that it is unknown which MMPs are expressed by Tregs and whether aVb8-mediated activation of latent TGF-β1 activation from the GARP/latent TGF-β1 complex is dependent on MMPs.

Helios+Tregs are less efficient at producing biologically active TGF-β1

Because we found that Helios+ Tregs expressed substantially higher levels of Itgβ8 (Fig. 2B), we wished to assess the ability of the Helios+ versus Helios−/low Tregs to drive Th17 differentiation in the same experimental setup as used in Fig. 5. When using plate-bound anti-CD3 to activate the cells in the culture, Helios+ Tregs were more efficient at driving Th17 differentiation (Fig. 6A, 6C) than Helios−/low cells. This result is consistent with the higher level of expression of Itgb8 on the Helios+ cells. It is not due to an inability of the Helios−/low cells to express latent TGF-β1 on their surface, because total Tregs activated in vitro when gated on the Helios−/low or Helios+ subsets both have similar levels of latent TGF-β1 on their surface (Fig. 6D). It also remains possible that Helios−/low Tregs can process the latent-TGF-β1 by an αβ8-independent mechanism. Surprisingly, when the cocultures were

FIGURE 5. Treg-mediated Th17 differentiation requires activation of latent TGF-β1 via integrin αVβ8. (A) Naive CD45.1+ OT-II cells from Rag1−/− mice were activated by soluble anti-CD3 in the presence of IL-6, splenic DCs, and preactivated CD4+CD25+ T cells from Itgβ8−/low mice (CD4-CRE) or CRE− littermates. Cells were reactivated with Cell Stimulation Cocktail and Protein Transport Inhibitors and then stained for CD4, CD45.1, CD45.2, and IL-17A. The percentage of IL-17A+ cells derived from the CD4+CD45.1+CD45.2− cells in the culture are shown in each panel. (B) Same as in (A), except in the presence of IL-2 (100 U/ml). Culture was stained for CD4, CD45.1, CD45.2, and intracellularly for Foxp3. (C and D) Same culture set up as in (A), except using preactivated CD4+CD25+ T cells from Itgβ8− or Lrrc32−/low mice or CRE− littermates. In the right panel, half of the CD4+CD25+ T cells were from Itgβ8−/low mice and half were from Lrrc32−/low mice. (D) Bar graph indicates the average (± SD) of duplicates within the experiment from (C). (E) Same as in (A), except using sorted CD4+Foxp3+ cells from Foxp3-GFP reporter mice and plate-bound anti-CD3 to activate the cells in the culture. Cells were cultured in the presence of a vehicle control (DMSO), the MMP-inhibitor GM6001, or the GM6001 control and measured for IL-17A as in (A).

The Journal of Immunology

2847

by guest on May 29, 2017 http://www.jimmunol.org/ Downloaded from
activated using soluble anti-CD3 with splenic DCs, which both the Helios and Helios-low Tregs were equally capable of driving Th17 differentiation (Fig. 6B, 6C). Because splenic DCs were unable to restore bioologically active TGF-$\beta_1$ production from Itgb8 KO Tregs (Fig. 5A), it is unlikely that low levels of Itgb8 on the DCs contribute to TGF-$\beta_1$ activation, but instead, it is possible that the DCs act as a platform to force a close proximity between the Tregs and naive T cells, thus resulting in a decreased threshold for TGF-$\beta_1$ concentrations. As a result, lower levels of bioologically active TGF-$\beta_1$ produced by Helios-low (Fig. 6A, 6C) are sufficient to drive a full response in the presence of DCs (Fig. 6B, 6C).

Discussion

TGF-$\beta_1$ is critical to the maintenance of immune homeostasis as deletion of TGF-$\beta_1$ results in a generalized inflammatory syndrome and autoimmunity. T and B lymphocytes play a critical role in disease development in TGF-$\beta_1^{-/-}$ mice as inflammation does not develop in TGF-$\beta_1^{-/-}$ mice on a SCID background (19).

Almost every cell type expresses TGF-$\beta_1$ receptors, but TGF-$\beta_1$ is always produced in an inactive form associated with LAP that prevents its binding to its receptor. Activation of TGF-$\beta_1$ is regulated so that its effects can be mediated in an appropriate environment. A number of mechanisms have been proposed for the activation of TGF-$\beta_1$ including plasmin, matrix metalloproteases, lysosomal proteases, and thrombospondin. Recent studies have demonstrated that physiologically, integrins are the key activators of TGF-$\beta_1$. The strongest evidence in favor of this is that mice with a single point mutation in the RGD sequence of integrin a8b1 develop systemic autoimmunity and colitis and may also have a defect in generating Tregs (4, 16). In addition, mice with a myeloid cell–specific b8 deficiency exhibit a reduction in Th17 cells and are protected from experimental autoimmune encephalomyelitis (5). Importantly, the same myeloid cell must both present the Ag and express the integrin. It is unclear why the expression of $\alpha_b\beta_8$ on cells on DCs is so critical for the maintenance of immune homeostasis, while loss of $\alpha_b\beta_8$ expression on Treg does not lead to a defect in immune regulation, at least in the steady state. One possibility is that the number of DCs that express $\alpha_b\beta_8$ is much higher than the number of $\alpha_b\beta_8$ expressing Tregs and that they are much more broadly distributed in the body. However, this is clearly not the case because $\alpha_b\beta_8$ expression is highly restricted to intestinal CD103+ DC, and $\alpha_b\beta_8$ expression is not detected on splenic DC (16). The most likely explanation for the different phenotypes of $\beta_8^{-/-}$ DC and T cells is that DCs are constantly exposed to the large latent complex at sites where they access it in the extracellular matrix. Furthermore, in the gut, potentiation of Th17 induction may be modulated by the intestinal microflora and Treg induction can be enhanced by the production of retinoic acid by the CD103+ DC. In contrast, although Tregs express relatively high levels of $\alpha_b\beta_8$ (Fig. 1), Tregs only express the latent TGF-$\beta_1$/GARP complex when ac-
tivated and the conditions leading to expression of this complex in vivo have yet to be defined.

It remains unclear why Tregs should express a second pathway for the delivery and activation of TGF-β1 on their cell surface. We have demonstrated that Treg-derived active TGF-β1 can play a role both in the differentiation of iTreg and Th17 cells. Tregs may primarily exert their effects via recognition of self-antigens during the process of priming and differentiation of naïve T cells on the surface of Ag-presenting DCs. It is likely that not all DCs express Itgb8 and that Treg intrinsic expression of Itgb8 may be required to facilitate activation of Treg-expressed latent TGF-β1 during the priming/differentiation of naïve T cells. Depending on the makeup of the inflammatory environment (IL-2 versus IL-6), Treg-derived active TGF-β1 would then promote infectious tolerance [existing Tregs driving de novo Treg differentiation (22)] by the generation of iTreg or promote the induction of potentially regulatory or pathogenic Th17 cells.

Acknowledgments
We thank Julie Edwards and Carol Henry from the NIAID Flow Cytometry Section for sorting our cells.

Disclosures
The authors have no financial conflicts of interest.

References